Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

11/14/24 5:45:56 PM ET

$ATXS

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ATXS alert in real time by email

SC 13G/A 1 tm2428137d1_sc13ga.htm SC 13G/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Astria Therapeutics, Inc.

(Name of Issuer)

Common stock, $0.001 par value per share

(Title of Class of Securities)

04635X 10 2

(CUSIP Number)

September 30, 2024

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨	Rule 13d-1(b)

x	Rule 13d-1(c)

¨	Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 04635X 10 2

Page 2 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners III, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “*SEC*”) on August 12, 2024.

CUSIP No. 04635X 10 2

Page 3 of 14

1.	Names of Reporting Persons VHCP Co-Investment Holdings III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 4 of 14

1.	Names of Reporting Persons Venrock Healthcare Capital Partners EG, L.P.
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) PN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 5 of 14

1.	Names of Reporting Persons VHCP Management III, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 6 of 14

1.	Names of Reporting Persons VHCP Management EG, LLC
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) OO

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 7 of 14

1.	Names of Reporting Persons Shah, Nimish
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 8 of 14

1.	Names of Reporting Persons Koh, Bong
2.	Check the Appropriate Box if a Member of a Group (See Instructions) (a) x (1) (b) ¨
3.	SEC Use Only
4.	Citizenship or Place of Organization United States
Number of Shares Beneficially Owned by Each Reporting Person With		5.	Sole Voting Power 0
		6.	Shared Voting Power 3,458,645 (2)
		7.	Sole Dispositive Power 0
		8.	Shared Dispositive Power 3,458,645 (2)
9.	Aggregate Amount Beneficially Owned by Each Reporting Person 3,458,645 (2)
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨
11.	Percent of Class Represented by Amount in Row (9) 6.1% (3)
12.	Type of Reporting Person (See Instructions) IN

(1)	Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah and Bong Koh are members of a group for the purposes of this Schedule 13G/A.

(2)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P.

(3)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

CUSIP No. 04635X 10 2

Page 9 of 14

Introductory Note: This Schedule 13G/A is filed on behalf of Venrock Healthcare Capital Partners III, L.P., a limited partnership organized under the laws of the State of Delaware (“*VHCP III LP”), VHCP Co-Investment Holdings III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Co-Investment III”), Venrock Healthcare Capital Partners EG, L.P., a limited partnership organized under the laws of the State of Delaware (“VHCP EG”), VHCP Management III, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management III”), VHCP Management EG, LLC, a limited liability company organized under the laws of the State of Delaware (“VHCP Management EG” and collectively with VHCP III LP, VHCP Co-Investment III, VHCP EG and VHCP Management III, the “Venrock Entities”), Nimish Shah (“Shah”) and Bong Koh (“Koh*”) in respect of the Common Stock of Astria Therapeutics, Inc.

Item 1.
	(a)	Name of Issuer Astria Therapeutics, Inc.

	(b)	Address of Issuer’s Principal Executive Offices 22 Boston Wharf Road, 10th Floor Boston, MA 02210

Item 2.
	(a)	Name of Person Filing Venrock Healthcare Capital Partners III, L.P. VHCP Co-Investment Holdings III, LLC Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC VHCP Management EG, LLC Nimish Shah Bong Koh

	(b)	Address of Principal Business Office or, if none, Residence New York Office: 7 Bryant Park 23rd Floor New York, NY 10018	Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304

	(c)	Citizenship All of the Venrock Entities were organized in Delaware. The individuals are both United States citizens.

	(d)	Title of Class of Securities Common Stock, $0.001 par value

	(e)	CUSIP Number 04635X 10 2

CUSIP No. 04635X 10 2

Page 10 of 14

Item 3.	If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
	Not applicable

Item 4.	Ownership
	(a)	Amount beneficially owned as of September 30, 2024:

			Venrock Healthcare Capital Partners III, L.P.	3,458,645 (1)
			VHCP Co-Investment Holdings III, LLC	3,458,645 (1)
			Venrock Healthcare Capital Partners EG, L.P.	3,458,645 (1)
			VHCP Management III, LLC	3,458,645 (1)
			VHCP Management EG, LLC	3,458,645 (1)
			Nimish Shah	3,458,645 (1)
			Bong Koh	3,458,645 (1)

	(b)	Percent of class as of September 30, 2024:

			Venrock Healthcare Capital Partners III, L.P.	6.1% (2)
			VHCP Co-Investment Holdings III, LLC	6.1% (2)
			Venrock Healthcare Capital Partners EG, L.P.	6.1% (2)
			VHCP Management III, LLC	6.1% (2)
			VHCP Management EG, LLC	6.1% (2)
			Nimish Shah	6.1% (2)
			Bong Koh	6.1% (2)

	(c)	Number of shares as to which the person has, as of September 30, 2024:

		(i)      Sole power to vote or to direct the vote:

			Venrock Healthcare Capital Partners III, L.P.	0
			VHCP Co-Investment Holdings III, LLC	0
			Venrock Healthcare Capital Partners EG, L.P.	0
			VHCP Management III, LLC	0
			VHCP Management EG, LLC	0
			Nimish Shah	0
			Bong Koh	0

CUSIP No. 04635X 10 2

Page 11 of 14

(ii)	Shared power to vote or to direct the vote:

		Venrock Healthcare Capital Partners III, L.P.	3,458,645 (1)
		VHCP Co-Investment Holdings III, LLC	3,458,645 (1)
		Venrock Healthcare Capital Partners EG, L.P.	3,458,645 (1)
		VHCP Management III, LLC	3,458,645 (1)
		VHCP Management EG, LLC	3,458,645 (1)
		Nimish Shah	3,458,645 (1)
		Bong Koh	3,458,645 (1)

(iii)	Sole power to dispose or to direct the disposition of:

		Venrock Healthcare Capital Partners III, L.P.	0
		VHCP Co-Investment Holdings III, LLC	0
		Venrock Healthcare Capital Partners EG, L.P.	0
		VHCP Management III, LLC	0
		VHCP Management EG, LLC	0
		Nimish Shah	0
		Bong Koh	0

(iv)	Shared power to dispose or to direct the disposition of:

		Venrock Healthcare Capital Partners III, L.P.	3,458,645 (1)
		VHCP Co-Investment Holdings III, LLC	3,458,645 (1)
		Venrock Healthcare Capital Partners EG, L.P.	3,458,645 (1)
		VHCP Management III, LLC	3,458,645 (1)
		VHCP Management EG, LLC	3,458,645 (1)
		Nimish Shah	3,458,645 (1)
		Bong Koh	3,458,645 (1)

(1)	Consists of (i) 612,982 shares held by Venrock Healthcare Capital Partners III, L.P.; (ii) 61,310 shares held by VHCP Co-Investment Holdings III, LLC; and (iii) 2,784,353 shares held by Venrock Healthcare Capital Partners EG, L.P. VHCP Management III, LLC is the general partner of Venrock Healthcare Capital Partners III, L.P. and the manager of VHCP Co-Investment Holdings III, LLC. VHCP Management EG, LLC is the general partner of Venrock Healthcare Capital Partners EG, L.P. Messrs. Shah and Koh are the voting members of VHCP Management III, LLC and VHCP Management EG, LLC.

(2)	This percentage is calculated based upon 56,425,282 shares of Common Stock outstanding as of July 31, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the SEC on August 12, 2024.

Item 5.	Ownership of Five Percent or Less of a Class
	If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ¨

CUSIP No. 04635X 10 2

Page 12 of 14

Item 6.	Ownership of More than Five Percent on Behalf of Another Person

	Not applicable

Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

	Not applicable

Item 8.	Identification and Classification of Members of the Group

	Not applicable

Item 9.	Notice of Dissolution of Group

	Not applicable

Item 10.	Certification

	By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect.

CUSIP No. 04635X 10 2

Page 13 of 14

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: November 14, 2024

Venrock Healthcare Capital Partners III, L.P.		Venrock Healthcare Capital Partners EG, L.P.

By:	VHCP Management III, LLC	By:	VHCP Management EG, LLC
Its:	General Partner	Its:	General Partner

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

VHCP Co-Investment Holdings III, LLC

By:	VHCP Management III, LLC
Its:	Manager

By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther
	Its: Authorized Signatory

VHCP Management III, LLC		VHCP Management EG, LLC

By:	/s/ Sherman G. Souther	By:	/s/ Sherman G. Souther
	Name: Sherman G. Souther		Name: Sherman G. Souther
	Its: Authorized Signatory		Its: Authorized Signatory

Nimish Shah

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

Bong Koh

/s/ Sherman G. Souther
Sherman G. Souther, Attorney-in-fact

CUSIP No. 04635X 10 2

Page 14 of 14

EXHIBITS

Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on January 2, 2024)

Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed January 2, 2024)

Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on January 2, 2024)

Get the next $ATXS alert in real time by email

Date	Price Target	Rating	Analyst
4/29/2025	$47.00	Overweight	Cantor Fitzgerald
1/31/2025	$26.00	Mkt Outperform	JMP Securities
7/29/2024	$35.00	Buy	TD Cowen
3/28/2023	$18.00	Outperform	Evercore ISI
9/29/2021	$20.00	Buy	Jefferies

Amendment: SEC Form SC 13G/A filed by Astria Therapeutics Inc.

Chat with this insight

Recent Analyst Ratings for
$ATXS

$ATXS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by CEO and President Milne Jill C.

SEC Form 4 filed by Chief Business Officer Matthews Andrea

SEC Form 4 filed by Chief Commercial Officer Komjathy Andrew

$ATXS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cantor Fitzgerald initiated coverage on Astria Therapeutics with a new price target

JMP Securities initiated coverage on Astria Therapeutics with a new price target

TD Cowen initiated coverage on Astria Therapeutics with a new price target

$ATXS
SEC Filings

SEC Form 10-Q filed by Astria Therapeutics Inc.

Amendment: SEC Form SCHEDULE 13G/A filed by Astria Therapeutics Inc.

SEC Form DEFA14A filed by Astria Therapeutics Inc.

$ATXS
Press Releases

Fastest customizable press release news feed in the world

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Annual Congress

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

$ATXS
Financials

Live finance-specific insights

Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE

Astria Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Corporate Update on Monday, November 13th

Astria Therapeutics Announces Exclusive Worldwide License Agreement with Ichnos Sciences for OX40 Portfolio

$ATXS
Large Ownership Changes

This live feed shows all institutional transactions in real time.